Access to and Payment for Office-Based Buprenorphine Treatment in Ohio

Importance: Office-based opiate agonist therapy has dramatically expanded access to medication-assisted treatment over the past decade but has also led to increased buprenorphine diversion. Objective: Our study sought to characterize physicians who participate in office-based therapy (OBT) to assess...

Full description

Bibliographic Details
Main Authors: Theodore V Parran, Joseph Z Muller, Elina Chernyak, Chris Adelman, Christina M Delos Reyes, Douglas Rowland, Mykola Kolganov
Format: Article
Language:English
Published: SAGE Publishing 2017-06-01
Series:Substance Abuse: Research and Treatment
Online Access:https://doi.org/10.1177/1178221817699247
id doaj-beaf43b7e28a42b3b2ea025dc5977e38
record_format Article
spelling doaj-beaf43b7e28a42b3b2ea025dc5977e382021-04-02T12:01:09ZengSAGE PublishingSubstance Abuse: Research and Treatment1178-22182017-06-011110.1177/1178221817699247Access to and Payment for Office-Based Buprenorphine Treatment in OhioTheodore V Parran0Joseph Z Muller1Elina Chernyak2Chris Adelman3Christina M Delos Reyes4Douglas Rowland5Mykola Kolganov6University Hospitals Case Medical Center, Cleveland, OH, USASchool of Medicine, Case Western Reserve University, Cleveland, OH, USAUniversity Hospitals Health System, St. Vincent Charity Medical Center, Cleveland, OH, USAUniversity Hospitals Health System, St. Vincent Charity Medical Center, Cleveland, OH, USAUniversity Hospitals Case Medical Center, Cleveland, OH, USASchool of Medicine, Case Western Reserve University, Cleveland, OH, USAUniversity Hospitals Health System, St. Vincent Charity Medical Center, Cleveland, OH, USAImportance: Office-based opiate agonist therapy has dramatically expanded access to medication-assisted treatment over the past decade but has also led to increased buprenorphine diversion. Objective: Our study sought to characterize physicians who participate in office-based therapy (OBT) to assess patient access to OBT in Ohio 10 years after its introduction. Design/Setting/Participants: Cross-sectional telephone survey of Drug Addiction Treatment Act–waivered physicians in Ohio listed by the Center for Substance Abuse Treatment (CSAT). Main Outcomes: This study sought to determine what proportion of eligible physicians are actively prescribing buprenorphine, whether they accept insurance for OBT, and whether they accept insurance for non-OBT services. In addition, we evaluated what physician characteristics predicted those primary outcomes. We hypothesized that a significant minority of eligible physicians are not active prescribers of buprenorphine. In addition, we expected that a significant minority of OBT prescribers do not accept insurance, further restricting patient access. We further hypothesized that a large subset of OBT prescribers accept insurance in their regular practices but do not take insurance for OBT. Results: Of the 466 listed physicians, 327 (70.2%) practice representatives were reached for interview. Thirty-three physicians were excluded, with a true response rate of 75.5%. In total, 80.7% of providers reached were active OBT prescribers. Of these, 52.7% accepted insurance for OBT, 20.8% accepted insurance for non-OBT services but not for OBT, and 26.5% did not accept insurance for any services. Practices who did not accept insurance were more likely among dedicated addiction clinics located outside of Ohio’s 6 major cities. Practices who normally accepted insurance but did not for OBT services were more likely in urban locations and were not associated with dedicated addiction practices. Neither business practice was associated with physician specialty Conclusions and Relevance: Access to OBT in Ohio is far lower than what the 466 listed physicians suggests. Nearly 1 in 5 of those physicians are not active OBT prescribers, and 1 in 2 active prescribers do not accept insurance for OBT. Further research is needed to determine whether practices who do not accept insurance provide care consistent with CSAT guidelines and whether such practice patterns contribute to buprenorphine diversion.https://doi.org/10.1177/1178221817699247
collection DOAJ
language English
format Article
sources DOAJ
author Theodore V Parran
Joseph Z Muller
Elina Chernyak
Chris Adelman
Christina M Delos Reyes
Douglas Rowland
Mykola Kolganov
spellingShingle Theodore V Parran
Joseph Z Muller
Elina Chernyak
Chris Adelman
Christina M Delos Reyes
Douglas Rowland
Mykola Kolganov
Access to and Payment for Office-Based Buprenorphine Treatment in Ohio
Substance Abuse: Research and Treatment
author_facet Theodore V Parran
Joseph Z Muller
Elina Chernyak
Chris Adelman
Christina M Delos Reyes
Douglas Rowland
Mykola Kolganov
author_sort Theodore V Parran
title Access to and Payment for Office-Based Buprenorphine Treatment in Ohio
title_short Access to and Payment for Office-Based Buprenorphine Treatment in Ohio
title_full Access to and Payment for Office-Based Buprenorphine Treatment in Ohio
title_fullStr Access to and Payment for Office-Based Buprenorphine Treatment in Ohio
title_full_unstemmed Access to and Payment for Office-Based Buprenorphine Treatment in Ohio
title_sort access to and payment for office-based buprenorphine treatment in ohio
publisher SAGE Publishing
series Substance Abuse: Research and Treatment
issn 1178-2218
publishDate 2017-06-01
description Importance: Office-based opiate agonist therapy has dramatically expanded access to medication-assisted treatment over the past decade but has also led to increased buprenorphine diversion. Objective: Our study sought to characterize physicians who participate in office-based therapy (OBT) to assess patient access to OBT in Ohio 10 years after its introduction. Design/Setting/Participants: Cross-sectional telephone survey of Drug Addiction Treatment Act–waivered physicians in Ohio listed by the Center for Substance Abuse Treatment (CSAT). Main Outcomes: This study sought to determine what proportion of eligible physicians are actively prescribing buprenorphine, whether they accept insurance for OBT, and whether they accept insurance for non-OBT services. In addition, we evaluated what physician characteristics predicted those primary outcomes. We hypothesized that a significant minority of eligible physicians are not active prescribers of buprenorphine. In addition, we expected that a significant minority of OBT prescribers do not accept insurance, further restricting patient access. We further hypothesized that a large subset of OBT prescribers accept insurance in their regular practices but do not take insurance for OBT. Results: Of the 466 listed physicians, 327 (70.2%) practice representatives were reached for interview. Thirty-three physicians were excluded, with a true response rate of 75.5%. In total, 80.7% of providers reached were active OBT prescribers. Of these, 52.7% accepted insurance for OBT, 20.8% accepted insurance for non-OBT services but not for OBT, and 26.5% did not accept insurance for any services. Practices who did not accept insurance were more likely among dedicated addiction clinics located outside of Ohio’s 6 major cities. Practices who normally accepted insurance but did not for OBT services were more likely in urban locations and were not associated with dedicated addiction practices. Neither business practice was associated with physician specialty Conclusions and Relevance: Access to OBT in Ohio is far lower than what the 466 listed physicians suggests. Nearly 1 in 5 of those physicians are not active OBT prescribers, and 1 in 2 active prescribers do not accept insurance for OBT. Further research is needed to determine whether practices who do not accept insurance provide care consistent with CSAT guidelines and whether such practice patterns contribute to buprenorphine diversion.
url https://doi.org/10.1177/1178221817699247
work_keys_str_mv AT theodorevparran accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio
AT josephzmuller accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio
AT elinachernyak accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio
AT chrisadelman accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio
AT christinamdelosreyes accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio
AT douglasrowland accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio
AT mykolakolganov accesstoandpaymentforofficebasedbuprenorphinetreatmentinohio
_version_ 1721570422168748032